Closing the gaps in treatment and management strategies in PAH
Publication
, Journal Article
Krasuski, RA
Published in: Journal of Managed Care Medicine
July 26, 2013
Pulmonary arterial hypertension (PAH ) is not typically diagnosed in a timely manner. It is now known that this condition affects all ages and genders and thus should be considered in patients with dyspnea, angina, fatigue, and syncope, particularly if they have other risk factors. There is no cure for PAH, but current approved treatment options that include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors can greatly improve a patient's quality of life and may improve survival.
Duke Scholars
Published In
Journal of Managed Care Medicine
ISSN
1094-1525
Publication Date
July 26, 2013
Volume
16
Issue
2
Start / End Page
9 / 13
Citation
APA
Chicago
ICMJE
MLA
NLM
Krasuski, R. A. (2013). Closing the gaps in treatment and management strategies in PAH. Journal of Managed Care Medicine, 16(2), 9–13.
Krasuski, R. A. “Closing the gaps in treatment and management strategies in PAH.” Journal of Managed Care Medicine 16, no. 2 (July 26, 2013): 9–13.
Krasuski RA. Closing the gaps in treatment and management strategies in PAH. Journal of Managed Care Medicine. 2013 Jul 26;16(2):9–13.
Krasuski, R. A. “Closing the gaps in treatment and management strategies in PAH.” Journal of Managed Care Medicine, vol. 16, no. 2, July 2013, pp. 9–13.
Krasuski RA. Closing the gaps in treatment and management strategies in PAH. Journal of Managed Care Medicine. 2013 Jul 26;16(2):9–13.
Published In
Journal of Managed Care Medicine
ISSN
1094-1525
Publication Date
July 26, 2013
Volume
16
Issue
2
Start / End Page
9 / 13